Diversification of circulating and tumor-infiltrating plasmacytoid DCs towards the P3 (CD80 + PDL1 - )-pDC subset negatively correlated with clinical outcomes in melanoma patients.

Our study shed light for the first time on the phenotypic and functional heterogeneity of pDCs in the blood and tumor of melanoma patients and their potential involvement in shaping clinical outcomes. Such novelty brightens our understanding of pDC complexity, and prompts the further deciphering of pDCs' features to better apprehend and exploit these potent immune players. It highlights the importance of considering pDC diversity when developing pDC-based therapeutic strategies to ensure optimal clinical success.